Vaxcyte, Inc. PCVX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Vaxcyte, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s return on equity?
- Vaxcyte, Inc. (PCVX) reported return on equity of -30.6% in Q1 2026.
- How has Vaxcyte, Inc.'s return on equity changed year-over-year?
- Vaxcyte, Inc.'s return on equity decreased by 55.4% year-over-year, from -19.7% to -30.6%.
- What is the long-term trend for Vaxcyte, Inc.'s return on equity?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s return on equity has grown at a -5.3% compound annual growth rate (CAGR), from -31.8% to -25.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.